Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology's Receivables history runs 3 years deep, the most recent figure standing at $7.0 million for Q2 2022.

• In Q2 2022, Receivables changed N/A year-over-year to $7.0 million; the TTM figure through Jun 2022 stood at $7.0 million (changed N/A YoY), while the FY2021 annual figure was $773.1 million, changed N/A from the prior year.
• Receivables came in at $7.0 million for Q2 2022 at Vir Biotechnology, down from $1.2 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.2 billion in Q1 2022 to a low of $3.8 million in Q2 2020.
• A 3-year average of $387.5 million and a median of $159.0 million in 2021 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 443.63% in 2022 and fell as far as 443.63% in 2022.
• Vir Biotechnology's Receivables stood at $3.8 million in 2020, then soared by 20244.18% to $773.1 million in 2021, then tumbled by 99.09% to $7.0 million in 2022.
• According to Business Quant data, Receivables over the past three periods registered $7.0 million, $1.2 billion, and $773.1 million for Q2 2022, Q1 2022, and Q4 2021 respectively.

Peer Comparison